Innovation Articles

31. Discovery Dialogues: Winston Haynes, VP, Computational Sciences and Engineering, LabGenius Tx 6/5/2026

    DDO interviewed Winston Haynes, VP, computational sciences and engineering, LabGenius Tx, on their T-cell engagers platform, including its lead candidate LGTX-101, a Nectin-4 CD3 molecule showing strong preclinical efficacy.

32. Fostering Entrepreneurial Mentorship And Education: A Peek Into Nucleate Boston Activator 2026 Cohort 6/3/2026

    Nucleate Boston’s 2026 Activator shows how mentorship, structure, and community can help promising young scientists become credible biotech founders.

33. DDW 2026 Signalled The Next Era Of Competitive Landscape In IBD 6/2/2026

    At the DDW 2026 meeting, the IBD landscape was portrayed as increasingly competitive and diversified, with emerging players and novel mechanisms challenging established standards of care.

34. Why Tolerability Will Drive The Next Wave Of Obesity Treatments 5/29/2026

    For the next generation of obesity medicines, enhancing how patients experience therapy will inform discovery and development efforts and may ultimately determine long-term success.

35. What Makes An RNA Platform Investable? Lessons From The Last Wave Of Biotech Financing 5/28/2026

    RNA investing has shifted from hype to scalability, forcing companies to prove manufacturability, delivery strength, and platform-wide value.

36. Synaptic Regeneration And The Future Of Alzheimer's R&D 5/22/2026

    For too long, treating Alzheimer’s disease has been a case of “managed decline.” We need to move beyond slowing disease progression toward achieving tangible functional recovery.

37. Unfolding Protein & Antibody Discovery At PEGS 2026 5/19/2026

    Our editorial team covers the 2026 Protein & Antibody Engineering Summit (PEGS) in Boston -- A working map of where biologics R&D is headed.

38. The Next Frontier In Women's Cancer Care: Combining Cell Therapy With Immuno-Oncology 5/19/2026

    The convergence of engineered cell therapies and immuno-oncology represents a significant step forward in the quest to improve outcomes for ovarian cancer patients.

39. From Urine-Derived To Recombinant Precision: KLK1 Reimagined For Preeclampsia 5/8/2026

    DiaMedica is testing a synthetic, first-in-class recombinant human kallikrein‑1 (rhKLK1) biologic in Phase 2 clinical trials to treat preeclampsia, which remains one of the most dangerous complications of pregnancy.

40. Why Rare Cancers Are Often Left Behind In Drug Discovery 4/23/2026

    Combining advances in AI with continued investment in rare cancer research could help bring new treatment options to patients who currently have very few.